Be part of the 11th Annual BioHealth Capital Region Forum, September 23–24, 2025, at US Pharmacopeia in Rockville, MD. This year’s theme, Where Human and Artificial Intelligence Converge in the BioHealth Industry, will explore groundbreaking advances shaping the future of healthcare. Connect with industry leaders, investors, government, and academia, and gain insights you can apply to your own organization.

Attendance is free thanks to our sponsors, but space is limited — secure your spot today.

The 2025 BioHealth Capital Region Investment Conference takes place on September 25 at US Pharmacopeia in Rockville, MD, and it is the premier venue for connecting innovative biohealth startups with venture capital, strategic investors, and industry partners. With more than 150 participants already registered, including over 60 companies and 40 investors, this year’s conference will feature curated 1:1 partnering meetings, dynamic quick-pitch sessions, and targeted networking designed to spark collaboration and investment. Whether you are raising capital or scouting the next big opportunity, this is the place to be. Register today!

Enjoy live music by The Impurities at the Wednesday evening reception on September 24 at USP. The band features USP team members showcasing their talent outside the lab, including Ron Piervincenzi, Ph.D., CEO, on guitar, Scott Bolgiano on guitar and backing vocals, John Daly on drums, Tim Greiner on lead vocals and harmonica, Alyssa Lang on vocals and saxophone, and Horacio Pappa on keyboards. It is a fun way to connect with peers after a full day of sessions.— register today for the Forum:

(RTTNews) - Precigen, Inc. (PGEN), a biopharmaceutical company focused on precision medicines, has entered into a credit facility agreement with funds managed by Pharmakon Advisors, LP.

The facility provides up to $125 million, including $100 million funded at closing and an additional $25 million available through March 31, 2027, subject to conditions. The agreement matures five years from the first funding and carries interest at 6.5% plus the three-month SOFR, with a 3.75% SOFR floor.

The financing strengthens Precigen's resources for the U.S. launch of PAPZIMEOS, its novel immunotherapy, and supports expansion into international and pediatric HPV-related indications. Evercore acted as financial advisor and Davis Polk LLP as legal counsel to Precigen, while Akin advised Pharmakon.

ROCKVILLE, Md., Sept. 5, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced new, positive data from the Phase I/II/III CAMPSIITE® trial of clemidsogene lanparvovec (RGX-121) for the treatment of patients with Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome, at the International Congress of Inborn Errors of Metabolism (ICIEM) 2025. REGENXBIO submitted these longer-term pivotal results to the U.S. Food and Drug Administration (FDA) in response to an information request in the ongoing Biologics License Application (BLA) review of RGX-121.

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAstat‑Dx Rise – a version of the QIAstat-Dx automated syndromic testing system that offers unparalled throughput with the easiest workflow available to customers worldwide.

The new system, which received clearance from the U.S. Food and Drug Administration (FDA), is designed to meet the needs of hospitals and reference laboratories seeking highly automated syndromic testing with automated loading and unloading of cartridges, access to priority handling of urgent samples and only a minimum of hands-on time.

FREDERICK, Md., Sept. 3, 2025 /PRNewswire/ -- BioFactura, Inc., a clinical‑stage biopharmaceutical company specializing in high‑value biosimilars and critical biodefense medical countermeasures, today announced the formation of Capitol Biologics, a new Contract Development and Manufacturing Organization (CDMO) division dedicated to supporting the process development, early‑phase clinical manufacturing, and analytical needs of emerging biotechnology companies and U.S. government agencies. Strategically located in the BioHealth Capital Region, Capitol Biologics combines technical excellence, regulatory expertise, and personalized collaboration to advance innovative biologics from lab bench to first‑in‑human studies.